Literature DB >> 29924454

Prognostic impact of doublecortin-like kinase 1 expression in locally advanced rectal cancer treated with preoperative chemoradiotherapy.

Yuzo Harada1, Shinsuke Kazama1,2, Teppei Morikawa3, Shigenobu Emoto1, Koji Murono1, Manabu Kaneko1, Kazuhito Sasaki1, Kensuke Otani1, Takeshi Nishikawa1, Toshiaki Tanaka1, Tomomichi Kiyomatsu1, Kazushige Kawai1, Keisuke Hata1, Hiroaki Nozawa1, Soichiro Ishihara1,4, Toshiaki Watanabe1.   

Abstract

Preoperative chemoradiotherapy (CRT) is a standard therapy for locally advanced rectal cancer; however, the response varies depending on cases. Therefore, CRT-response predictors need to be elucidated. Cancer stem cells (CSCs), comprising a small part of tumors, are associated with tumor progression and recurrence due to their self-renewal and proliferation abilities. Doublecortin-like kinase 1 (DCLK1) is one of the several putative CSC markers; however, the clinical impact of its expression in rectal cancer has not been evaluated. The aim of this study was to clarify the clinical impact of DCLK1 expression in rectal cancer. We immunohistochemically evaluated DCLK1 expression in surgical specimens of 106 rectal cancer patients, including those who underwent preoperative CRT. The correlations between DCLK1 expression, and clinicopathological features and patient prognosis were then assessed. In rectal cancer patients treated with preoperative CRT, DCLK1 expression was significantly correlated with lymph node metastasis (p = 0.02) and poor cancer-specific survival (p = 0.049). However, in patients treated without preoperative therapy, no such correlation was found. DCLK1 expression can be associated with lymph node metastasis and poor cancer-specific survival in rectal cancer patients who receive CRT.
© 2018 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DCLK1; chemoradiotherapy; immunohistochemistry; rectal cancer

Mesh:

Substances:

Year:  2018        PMID: 29924454     DOI: 10.1111/apm.12852

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  5 in total

Review 1.  Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis.

Authors:  Elham Kalantari; Mahdieh Razmi; Fatemeh Tajik; Mohsen Asadi-Lari; Roya Ghods; Zahra Madjd
Journal:  Cancer Cell Int       Date:  2022-06-18       Impact factor: 6.429

2.  LncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axis.

Authors:  Zhi-Qi Liu; Wei-Feng He; Yang-Jie Wu; Shun-Li Zhao; Ling Wang; Yan-Yi Ouyang; San-Yuan Tang
Journal:  BMC Gastroenterol       Date:  2020-05-18       Impact factor: 3.067

3.  Cancer Stem Cell Biomarkers Predictive of Radiotherapy Response in Rectal Cancer: A Systematic Review.

Authors:  Marzia Mare; Lorenzo Colarossi; Veronica Veschi; Alice Turdo; Dario Giuffrida; Lorenzo Memeo; Giorgio Stassi; Cristina Colarossi
Journal:  Genes (Basel)       Date:  2021-09-25       Impact factor: 4.096

4.  Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.

Authors:  Lanqing Wang; Lei Zhao; Zhenyu Lin; Dandan Yu; Min Jin; Pengfei Zhou; Jinghua Ren; Jing Cheng; Kunyu Yang; Gang Wu; Tao Zhang; Dejun Zhang
Journal:  Clin Transl Med       Date:  2022-05

5.  DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.

Authors:  Lorenzo Nevi; Sabina Di Matteo; Guido Carpino; Ilaria Grazia Zizzari; Safarikia Samira; Valeria Ambrosino; Daniele Costantini; Diletta Overi; Antonella Giancotti; Marco Monti; Daniela Bosco; Valerio De Peppo; Andrea Oddi; Agostino Maria De Rose; Maria Consiglia Bragazzi; Jessica Faccioli; Sara Massironi; Gian Luca Grazi; Pierluigi Benedetti Panici; Paquale Bartomeo Berloco; Felice Giuliante; Vincenzo Cardinale; Pietro Invernizzi; Giuseppina Caretti; Eugenio Gaudio; Domenico Alvaro
Journal:  Hepatology       Date:  2021-01       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.